Re: End of May These at 15p are cheap.
End of May Waiting over at the end of next month with critical updates on CD4.2015 looking positive.solid trading update and reads well and projects confidence.
Trading update due mid April Awaitng the trading update, the price is at rock bottom. Good news will lift it perhaps I'll wash my face but am deep under water at these price levels. Averaging down will further skew my portfolio's risk profile. We neede some positice news flow and revenue increases for this to recover to previous levels.
Re: CD4 testing Alere Some bored people exiting at tax year end?
Re: CD4 testing Alere Wouldn't be no surprise for there to be an approach. Makes a lot of sense but if it doesn't happen ODX should have no concerns about competing with Alere. Not all that good imho.
CD4 testing Alere Alere has a CD4 analyser in field, they are clearly very proud of their achievement. The video link below shows the nature of the problem faced by HIV testing in Africa which the current field testing of Visitect CD4 is undergoing in Kenya.[link] is a big healthcare business which has been veracquisative in the past under it's ex president Ron Zwanziger. David Evans non executive director has been associaited with a couple of businesses taken ove by Alere in Ron Zwanzigers time. We wait for jam tomorrow but there are big stakes at play.
Director buying Kieron Harbinson, Financial Director, bought 62,500 shares in the company on the 18th December 2014 at a price of 16.50p. ...
Director dealings I know there have been delays, but two days after their H1 results, its good to see three directors buying sharesavid Evans, Chairman, 173,500 at 15pJay Grewal, Sales & Marketing Director: 31,309 at 19.12pAndrew Shepard, CEO 30,974 at 17pThat's a total of over £37k. It's not ging to set the world alight, but what's interesting is the sales & marketing guy buying. The other two have 2.49% and 2.8% of the shares, but the sales & marketing guy is putting in his no doubt hard earnt cash into the business, and you'd hope he's aware of the future prospects.
Good H1 results today ....achieving 0.5p EPS in H1 despite the problems in Germany and some supply delays.The back orders falling into H2 for infectious diseases should mean an even brighter H2 given that food intolerance is booming. Forecasts of 1.2p EPS for the year look perfectly reasonable.ODX have £2.1m of cash, with relatively small long-term borrowings to offset, so should hopefully see no or minimal dilution over time - given the profitable core business - through to commercialisation of the Aids test and the allergy programme.